Clinical Trial Update: Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

This update describes a Phase 1 dose-defining study evaluating the AKT inhibitor MK-2206 in combination with gefitinib for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• MK-2206 (MK-2206)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: UNKNOWN